Bioretec Ltd Inside information 20 May 2024 at
6:00 p.m. EEST
TAMPERE, Finland, May 20, 2024 /PRNewswire/ -- Bioretec Ltd is
pleased to announce that Mr. Alan
Donze has been appointed CEO of Bioretec as of today,
20 May 2024. He will start in this
position immediately. With a distinguished career spanning the
banking and medical device industries, Mr. Donze brings a wealth of
experience and expertise to the Bioretec organization.
Mr. Donze began his career journey in the banking industry,
serving as the Vice President of Commercial Lending and Leveraged
Finance for a regional predecessor to Chase bank. He left banking
to begin his medical device career as a Regional Sales
Representative for Stryker Endoscopy in 1991. Over his 13 years at
Stryker, Mr. Donze's responsibilities increased to various senior
management positions, including Vice President General Manager of
Stryker Endoscopic Service and Vice President General Manager of
Stryker Communications, a division he was given the tremendous
opportunity to create and build from the ground up. Mr. Donze has
also held senior leadership positions for a number of other medical
device and technology companies including Smith+Nephew, Bioventus,
and Lima Corporate and venture-led startups such as Isotis
Orthobiologics, Aerobiotix and Rx.Health. Mr. Donze received his
Bachelor of Science in Finance from Louisiana
State University.
"We are excited to announce the appointment of Alan Donze as our new Chief Executive Officer.
With his proven track record of leadership and vision, we are
confident that Alan will lead our company to new heights of
commercial success. Alan brings with him 30 years of sales and
marketing leadership experience in medical devices, where he has
demonstrated a deep understanding of market dynamics and a
relentless drive for excellence. His strategic insights and passion
for Bioretec's mission make him the ideal leader to guide us into
the future," says Tomi Numminen,
Bioretec's Chairman of the Board.
"I am honored to be given the opportunity to lead Bioretec to
the next level and deeply appreciate the confidence placed in me by
the Board of Directors. Bioretec's groundbreaking work in
developing alternatives to traditional metal implants represents a
significant advancement in the medical field. Our products have the
potential to reduce the need for invasive surgeries and improve
patient outcomes, aligning with a critical need within the
healthcare community. I am eager to contribute to Bioretec's
mission by expanding our efforts to introduce these transformative
solutions to the benefit of many more patients. I look forward to
the journey ahead and to our continued growth and success," says
Alan Donze.
Timo Lehtonen, Bioretec's CEO
since 2019, will transfer to the position of Chief Technology
Officer (CTO) and continue to lead the development of Bioretec's
future product pipeline.
"It has been a privilege to lead Bioretec since 2019 and support
its remarkable growth through interesting, challenging times. I am
excited to focus my efforts on advancing the RemeOs™product
pipeline. Together with Alan, I am confident we will continue to
strengthen our growth and transform bone fracture care. In my
forthcoming role as CTO, I will leverage my extensive experience in
innovation, product development, and regulatory expertise to
support the management team and our skilled personnel. Our goal is
to achieve the best possible outcomes in redefining bone fracture
treatment and improving patients' quality of life," says
Timo Lehtonen.
"I would like to thank Timo
Lehtonen for his passionate and dedicated leadership as our
CEO over the past five years. Under his guidance, Bioretec has
grown strongly and strengthened its position as a leading innovator
in biodegradable technologies. With its biodegradable metal
implants, the company has significantly modernized the surgical
treatment of bone fractures, which significantly increases the
quality of the lives of the patients. Our mutual and succesful path
with Timo continues while he assumes the role of CTO in which role
he continues to provide important support for the future
development of our product pipeline," says Chairman of the Board
Tomi Numminen.
Further enquiries
Tomi Numminen, Chairman of the
Board, tel. +358 40 581 2132
Certified advisor
Nordic Certified Adviser AB, +46 70 551 67 29
Information about Bioretec
Bioretec is a globally operating Finnish medical device company
that continues to pioneer the application of biodegradable
orthopedic implants. The company has built unique competencies in
the biological interface of active implants to enhance bone growth
and accelerate fracture healing after orthopedic surgery. The
products developed and manufactured by Bioretec are used worldwide
in approximately 40 countries.
Bioretec is developing the new RemeOs™ product
line based on a magnesium alloy and hybrid composite,
introducing a new generation of strong biodegradable materials for
enhanced surgical outcomes. The RemeOs™ implants are absorbed and
replaced by bone, which eliminates the need for removal surgery
while facilitating fracture healing. The combination has the
potential to make titanium implants redundant and help clinics
reach their Value-Based Healthcare targets while focusing
on value for patients through efficient healthcare. The first
RemeOs™ product market authorization has been received in the U.S.
in March 2023, and in Europe, the CE-mark is expected to be received
during the second quarter of 2024. Bioretec is positioning itself
to enter the addressable USD 7
billion global orthopedic trauma market and become a game
changer in surgical bone fracture treatment.
Better healing - Better life. www.bioretec.com
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/bioretec/r/inside-information--alan-donze-has-been-appointed-as-bioretec-s-new-ceo,c3984605
The following files are available for download:
https://news.cision.com/bioretec/i/alan-donze,c3302148
|
Alan Donze
|
https://mb.cision.com/Public/20509/3984605/b152b5ed9efe14f4.pdf
|
Bioretec CEO release
2024-05-20 EN final
|
View original
content:https://www.prnewswire.co.uk/news-releases/inside-information-alan-donze-has-been-appointed-as-bioretecs-new-ceo-302150248.html